Homocysteine, levodopa and Parkinson's disease;Homocysteín, levodopa a Parkinsonova choroba

Ceska a Slovenska Neurologie a Neurochirurgie

Volumn 69, Issue 3, 2006, Pages 183-188

  Valkovič, Peter ^a,b   Blazicek P ^a   Benetin, J ^a   Kukumberg, P ^a  

^a LF UK ^*  (Slovakia)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

B vitamins; Homocysteine; Levodopa; Parkinson's disease; Therapy

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYANOCOBALAMIN; ENTACAPONE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; VITAMIN B GROUP;

AMINO ACID BLOOD LEVEL; ATHEROSCLEROSIS; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DISEASE EXACERBATION; ENZYME INHIBITION; HUMAN; HYPERHOMOCYSTEINEMIA; LONG TERM CARE; PARKINSON DISEASE; PROGNOSIS; REVIEW; RISK FACTOR; THROMBOSIS; VASCULAR DISEASE; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 33745054963     PISSN: 12107859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Cotzias GC, Papavasiliou PS, Gellene R. Experimental treatment of parkinsonism with L-Dopa. Neurology 1968; 18: 276-7.
2. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004; 19: 997-1005.
3. Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, et al. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clin Chem 2001; 47: 1102-4.
4. Miller JW, Selbub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003; 60: 1125-9.
5. Müller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet 1999; 354: 126-7.
6. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003; 60: 59-64.
7. Valkovič P, Benetin J, Blaźíček P, Valkovičová L, Gmitterová K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005; 11: 253-6.
8. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003; 108: 66-7.
9. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 1998; 157 (Suppl 2): S40-S44.
10. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19: 217-46.
11. American Society of Human Genetics/American College of Medical Genetics Test and Transfer Committee Working Group. Measurement and use of total plasma homocysteine. Am J Hum Genet 1998; 63: 1541-3.
12. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-50.
13. Genest JJ, Jr., McNamara JR, Upson B, Salem DN, Ordovas JM, Schaefer EJ, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb 1991; 11: 1129-36.
14. Morris MS, Jacques PF, Rosenberg IH, Selhub J, Bowman BA, Gunter EW, et al. Serum total homocysteine concentration is related to self-reported heart attack or stroke history among men and women in the NHANES III. J Nutr 2000; 130: 3073-6.
15. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-8.
16. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-91.
17. Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 2002; 16: 391-9.
18. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003; 41: 1392-403.
19. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-28.
20. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
21. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-83.
22. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2003; 2: 425-8.
23. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-57.
24. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-27.
25. Folbergrová J. Anticonvulsant action of both NMDA and non-NMDA receptor antagonists against seizures induced by homocysteine in immature rats. Exp Neurol 1997; 145: 442-50.
26. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 1997; 94: 5923-28.
27. Drobný M, Kurča E. Possible extrapyramidal system degradation in Parkinson's disease. Brain Res Bull 2000; 53: 425-30.
28. Allain P, Le BA, Cordillet E, Le QL, Bagheri H, Montastruc JL. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 1995; 16: 527-9.
29. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998; 40: 225-7.
30. Miller JW. Homocysteine, folate deficiency, and Parkinson's disease. Nutr Rev 2002; 60: 410-3.
31. Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y, et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 2003; 207: 19-23.
32. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000; 55: 437-40.
33. Zoccolella S, Lamberti P, Armenise E, de Mari M, Lamberti SV, Mastronardi R, et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 2005; 11: 131-3.
34. O'Suilleabhain PE, Bottiglieri T, Dewey RB, Jr., Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004; 19: 1403-8.
35. Levy G, Tang MX, Louis ED, Cote LJ, Alfaro B, Mejia H, et al. The association of incident dementia with mortality in PD. Neurology 2002; 59: 1708-13.
36. Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study. Acta Neuropathol (Berl) 2003; 105: 415-9.
37. Rektorová I. Účinek donepezilu na demenci u Parkinsonovy nemoci a Alzheimerovy nemoci. Pilotní studie. Čes a slov Neurol Neurochir 2004; 67/100: 359-63.
38. Kubová D, Rektor I. Vaskulární parkinsonský syndrom - historie a současnost. Čes a slov Neurol Neurochir 2001; 64/97: 75-81.
39. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-37.
40. O'Suilleabhain PE, Sung V, Hernandez C, Lacritz; L, Dewey RB, Jr., Bottiglieri T, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004; 61: 865-8.
41. Zoccolella S, Lamberti P, Iliceto G, Diroma C, Armenise E, Defazio G, et al. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med 2005; 43: 1107-10.
42. Hadj Tahar A, Gregoire L, Darre A, Belanger N, Meltzer L, Bedard PJ. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neuro-biol Dis 2004; 15: 171-6.
43. Bareš M, Kaňovský P, Rektor I. Úloha inhibitorů katechol-O-metyl-transferázy (COMT) v léčbě pozdních komplikací Parkinsonovy nemoci - účinnost a bezpečnost entakaponu (Comtan®). Čes a slov Neurol Neurochir 2002; 65/98: 69-75.
44. Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 2005; 20: 69-72.
45. Lamberti P, Zoccolella S, Armenise E, Lamberti SV, Fraddosio A, de Mari M, et al. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005; 12: 365-8.
46. Mudd SH, Poole JR. Labile methyl balances for normal humans on various dietary regimens. Metabolism 1975; 24: 721-35.
47. Stead LM, Au KP, Jacobs RL, Brosnan ME, Brosnan JT. Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate. Am J Physiol Endocrinol Metab 2001; 281: E1095-E1100.